Anandamide hydrolysis: a new target for anti-anxiety drugs?
by
Gaetani S, Cuomo V, Piomelli D.
Department of Psychiatry,
University of California,
Irvine, CA 92697-4625, USA.
Trends Mol Med. 2003 Nov;9(11):474-8.
ABSTRACTThe major psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol, affects emotional states in humans and laboratory animals by activating brain cannabinoid receptors. A primary endogenous ligand of these receptors is anandamide, the amide of arachidonic acid with ethanolamine. Anandamide is released in selected regions of the brain and is deactivated through a two-step process consisting of transport into cells followed by intracellular hydrolysis. Pharmacological blockade of the enzyme fatty acid amide hydrolase (FAAH), which is responsible for intracellular anandamide degradation, produces anxiolytic-like effects in rats without causing the wide spectrum of behavioral responses typical of direct-acting cannabinoid agonists. These findings suggest that anandamide contributes to the regulation of emotion and anxiety, and that FAAH might be the target for a novel class of anxiolytic drugs.THC
Bliss
Aerosol
Memory
Anandamide
Just say know
Tolerant mice
Forgetful rodents
Endocannabinoids
Stoned as a newt?
The nectar of delight
Stoned chocaholics?
Cannabis Abuse Disorder
Cannabis and schizophrenia
Cannabinoids/Parkinson's disease
Anandamide and the hedonic hotspot
Cannabis, anandamide and 'runner's high'
Anandamide hydrolysis inhibitors as anti-anxiety drugs01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Refs
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family
